Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?

  • Nabil Ismaili | ismailinabil@yahoo.fr Centre d’oncologie, CHU Mohamed VI, Marrakech, Morocco.
  • Sanaa Elmajjaoui Institut National d’Oncologie, Rabat, Morocco.
  • Youssef Bensouda Institut National d’Oncologie, Rabat, Morocco.
  • Rhizlane Belbaraka Centre d’oncologie, CHU Mohamed VI, Marrakech, Morocco.
  • Halima Abahssain Institut National d’Oncologie, Rabat, Morocco.
  • Wafa Allam Institut National d’Oncologie, Rabat, Morocco.
  • Zouhour Fadoukhair Institut National d’Oncologie, Rabat, Morocco.
  • Mohamed Mesmoudi Institut National d’Oncologie, Rabat, Morocco.
  • Rachid Tanz Institut National d’Oncologie, Rabat, Morocco.
  • Tarik Mahfoud Institut National d’Oncologie, Rabat, Morocco.
  • Abdelhamid Elomrani Centre d’oncologie, CHU Mohamed VI, Marrakech, Morocco.
  • Mouna Khouchani Centre d’oncologie, CHU Mohamed VI, Marrakech, Morocco.
  • Yassir Sbitti Institut National d’Oncologie, Rabat, Morocco.
  • Noureddine Benjaafar Institut National d’Oncologie, Rabat, Morocco.
  • Hassan Errihani Institut National d’Oncologie, Rabat, Morocco.
  • Ali Tahri Centre d’oncologie, CHU Mohamed VI, Marrakech, Morocco.

Abstract

Bladder cancer is the fourth most common cancer for men and the eighth most common cancer for women. Transitional cell carcinoma is the most predominant histological type. Bladder cancer is highly chemosensitive. In metastatic setting the treatment is based on cisplatin chemotherapy regimens type MVAC, MVAC-HD or gemcitabine plus cisplatin. The standard treatment of muscle invasive operable bladder cancer (T2–T4) used widely was radical cystectomy with pelvic lymph nodes dissection; the anatomical extent of pelvic lymphadenectomy has not accurately been defined so far. However, in the last decade, the treatment of tumors was improved by the introduction of chemotherapy as part of the management of the disease. Neoadjuvant chemotherapy should be considered at first, as standard treatment of choice, before local treatment for patients with good performance status (0–1) and good renal function–glomerular filtration rate (GFR) >60 mL/min. For patients treated with primary surgery, adjuvant chemotherapy is a valuable option in the case of lymph nodes involvement. This brief review would provide the evidence of the role of neoadjuvant chemotherapy in the management of operable muscle invasive (T2–T4) bladder cancer.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-09-30
Info
Issue
Section
Reviews
Keywords:
Bladder cancer – Chemotherapy – Neoadjuvant chemotherapy – Adjuvant chemotherapy
Statistics
  • Abstract views: 2023

  • FULL TEXT: 225
How to Cite
Ismaili, N., Elmajjaoui, S., Bensouda, Y., Belbaraka, R., Abahssain, H., Allam, W., Fadoukhair, Z., Mesmoudi, M., Tanz, R., Mahfoud, T., Elomrani, A., Khouchani, M., Sbitti, Y., Benjaafar, N., Errihani, H., & Tahri, A. (2011). Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?. Oncology Reviews, 5(3), 185-189. https://doi.org/10.4081/oncol.2011.33